Visible Genetics completes $7 million financing:
This article was originally published in Clinica
Executive Summary
The Canadian company, Visible Genetics, has completed a $7 million private financing with a group of private and institutional investors. The one-year loan carries 10% interest. The investors also have the right to buy 420,000 shares at $10 each, which is valid up to April 29, 2003. The Toronto company also released its first-quarter results. Sales were $1.1 million, compared with $312,572 for the first quarter of 1997. The company's net loss increased from $1.9 million to $3 million, largely due to the expansion costs of its factory in Toronto and the establishment of a European sales force.
You may also be interested in...
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.